Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Where this comes from
- Record sourced from PubMed, PMID 23704555.
- Also identified by DOI 10.1126/science.1235505.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Apolipoproteins E
- Brain
- Tetrahydronaphthalenes